{
    "clinical_study": {
        "@rank": "70685", 
        "arm_group": {
            "arm_group_label": "Nasopharyngeal cancers", 
            "description": "Intensitiy modulated radiotherapy with chemotherapy"
        }, 
        "brief_summary": {
            "textblock": "In the treatment of nasopharyngeal cancers, to determine the incidence of high grade  (\u2265G2)\n      subjective xerostomia at 1 year."
        }, 
        "brief_title": "Parotid-sparing IMRT for Nasopharyngeal Cancer", 
        "completion_date": {
            "#text": "April 2012", 
            "@type": "Actual"
        }, 
        "condition": [
            "Nasopharyngeal Cancers", 
            "Intensity Modulated Radiotherapy With Chemotherapy"
        ], 
        "condition_browse": {
            "mesh_term": "Nasopharyngeal Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "The purpose of this study was to determine the feasibility in delivering induction\n      chemotherapy and concomitant chemotherapy with IMRT in the treatment of locally advanced\n      nasopharyngeal cancers and to determine the incidence of high grade (\u2265G2) subjective\n      xerostomia at 1 year."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  nasopharyngeal cancers\n\n        Exclusion Criteria:\n\n          -  Patients <16 years old or with a previous malignancy other than non-melanomatous skin\n             cancer were excluded"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "16 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "nasopharyngeal cancers"
            }
        }, 
        "enrollment": {
            "#text": "42", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 26, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02149641", 
            "org_study_id": "CCR2608"
        }, 
        "intervention": {
            "arm_group_label": "Nasopharyngeal cancers", 
            "intervention_name": "Intensity modulated radiotherapy with chemotherapy", 
            "intervention_type": "Radiation"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 26, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "United Kingdom", 
                    "zip": "SW3 6JJ"
                }, 
                "name": "The Royal Marsden NHS Foundation Trust"
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_groups": "1", 
        "official_title": "Phase II Study of Parotid Sparing IMRT for Nasopharyngeal Cancer", 
        "overall_official": {
            "affiliation": "The Royal Marsden NHS Foundation Trust", 
            "last_name": "Christopher M Nutting, FRCR", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United Kingdom: Royal Marsden CCR and Local and National Research Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "the incidence of \u2265G2 xerostomia at 1 year using the subjective component LENTSOMA", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02149641"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Acute radiation toxicities", 
                "safety_issue": "No", 
                "time_frame": "0-3 months"
            }, 
            {
                "measure": "Late radiation toxicities", 
                "safety_issue": "No", 
                "time_frame": "3-24 months"
            }, 
            {
                "measure": "loco-regional disease-free survival (LRDFS), progression-free survival (PFS) and overall survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "chemotherapy compliance and toxicities", 
                "safety_issue": "No", 
                "time_frame": "0-12 weeks"
            }
        ], 
        "source": "Royal Marsden NHS Foundation Trust", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Royal Marsden NHS Foundation Trust", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2006", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}